Amplia Therapeutics (ASX:ATX) Total Assets: A$41.44 Mil (As of Mar. 2026)


ASX:ATX Amplia Therapeutics Ltd ASX:ATX
36 GF Score
Price A$0.15
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Total Assets?

Amplia Therapeutics ASX:ATX +11.11% 36 Total Assets is A$41.44 Mil as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Amplia Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was A$41.44 Mil.

During the past 12 months, Amplia Therapeutics's average Total Assets Growth Rate was 12.50% per year. During the past 3 years, the average Total Assets Growth Rate was 13.00% per year. During the past 5 years, the average Total Assets Growth Rate was -1.70% per year. During the past 10 years, the average Total Assets Growth Rate was 30.90% per year.

During the past 13 years, Amplia Therapeutics's highest 3-Year average Total Assets Growth Rate was 201.40%. The lowest was -16.20%. And the median was 9.95%.

Total Assets is connected with ROA %. Amplia Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -16.43%. Total Assets is also linked to Revenue through Asset Turnover. Amplia Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Amplia Therapeutics  (ASX:ATX) Total Assets Explanation

Total Assets is connected with ROA %.

Amplia Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-7.062/( (44.54+41.441)/ 2 )
=-7.062/42.9905
=-16.43 %

Note: The Net Income data used here is two times the semi-annual (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Amplia Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (44.54+41.441)/ 2 )
=0/42.9905
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Amplia Therapeutics Total Assets Related Terms

Amplia Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Total Assets Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.48 18.68 14.85 22.94 41.44

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.85 14.20 22.94 44.54 41.44
ASX:ATX
36GF Score
Amplia Therapeutics Ltd ASX:ATX
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Amplia Therapeutics's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (A: Mar. 2026 )+Total Liabilities (A: Mar. 2026 )
=39.472+1.969
=41.44

Amplia Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=39.472+1.969
=41.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of A$41.44 Mil mean?
Amplia Therapeutics (ASX:ATX) has a Total Assets of A$41.44 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Amplia Therapeutics and its competitors.
Is Amplia Therapeutics' Total Assets too high?
Amplia Therapeutics' current Total Assets is A$41.44 Mil. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Total Assets compare to VRTX and REGN?
Amplia Therapeutics' Total Assets of A$41.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current Total Assets is A$41.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Total Assets of A$41.44 Mil. The current Total Assets is A$41.44 Mil. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Total Assets is A$41.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score

Get the complete analysis for ASX:ATX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price